Key Stats for IBRX Stock
- Price Change for VRE stock: +17.50%
- IBRX Share Price as of Feb. 24: $11.55
- 52-Week High: $12.28
- IBRX Stock Price Target: $11.60
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
ImmunityBio (IBRX) stock’s rally followed a set of announcements tied to ANKTIVA’s commercial momentum. The company reported FY 2025 net product revenue of $113 million. ImmunityBio described that as about 700% year-over-year growth.
The company also highlighted regulatory progress outside the U.S. ImmunityBio announced European Commission conditional marketing authorization for ANKTIVA in combination with BCG for certain NMIBC CIS patients. It also announced Saudi FDA accelerated approvals for ANKTIVA in bladder cancer and for use with checkpoint inhibitors in metastatic NSCLC.
ImmunityBio also pointed to new commercialization infrastructure and partnerships. The company announced a European distribution partnership with Accord Healthcare and opened an Irish subsidiary to support a European launch. It also announced a partnership to launch ANKTIVA in Saudi Arabia, alongside broader regional expansion efforts.
See analysts’ growth forecasts and price targets for IBRX stock (It’s free!) >>>
What the Market Is Telling Us About IBRX Stock
The market move suggests investors are re-pricing IBRX around a faster commercial ramp. ImmunityBio’s LTM revenue is $113.3 million, with a 99.3% gross margin. That combination can look compelling when revenue is scaling from a low base.
At the same time, profitability remains a key constraint. The company’s LTM EBIT margin is (213.6%), and LTM EBITDA is (226.5) million. ImmunityBio also reported a negative free cash flow of about (398.1) million over the LTM period.
The balance sheet adds another layer of sensitivity. LTM net debt is about $603.5 million, and net debt to EBITDA is shown as (2.66x) due to negative EBITDA. With the stock near its 52-week high, sentiment can swing quickly on new clinical, regulatory, or financing updates.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in ImmunityBio, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IBRX, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IBRX alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze ImmunityBio stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
